Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GSK-3 as a Target for Lithium-charged Au Nanoparticles in Bipolar Disorder

NCT07732933 is registered in ClinicalTrials.gov with Fondazione Policlinico Universitario Agostino Gemelli IRCCS as lead sponsor.

NCT NCT07732933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07732933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GSK-3 as a Target for Lithium-charged Au Nanoparticles in Bipolar Disorder
Lead sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
March 31, 2029
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar disorder (bd), bipolar disorder (bpd)